Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers have emerged as key predictive biomarkers in EGFR tyrosine kinase inhibitor (TKI) treatment. However, a few patients with wild-type EGFR also respond to EGFR TKIs. This study investigated the factors predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seo Yun, Myung, Jae Kyung, Kim, Hye-Ryoun, Na, Im Il, Koh, Jae Soo, Baek, Hee Jong, Kim, Cheol Hyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304331/
https://www.ncbi.nlm.nih.gov/pubmed/29926551
http://dx.doi.org/10.4046/trd.2018.0004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304331/
https://www.ncbi.nlm.nih.gov/pubmed/29926551
http://dx.doi.org/10.4046/trd.2018.0004

Ejemplares similares